Over the last decade, digital therapeutics have been gaining steam. In part, this shift is aided by the adoption of connected medical tools during the COVID-19 pandemic and the ongoing push toward more of a hybrid care model. However, the technologies have largely not yet hit the mainstream market.
Today, industry players are looking to get stakeholders from the provider, payer and life science...
Digital healths’ moment in the sun doesn’t appear to be ending anytime soon, and one area that is just beginning its journey into virtual care is the pharmaceutical industry.
In recent years, pharma has taken an interest in the digital health space, and even before the pandemic hit, experts from HealthXL expected 2020 to be a big year for digital therapeutics in pharma.
This morning at the DTx...
For digital therapeutics companies, the FDA has often been viewed as the gatekeeper to getting products to the patients. However, today the conversation around efficacy and research is branching beyond just what ticks the FDA boxes, into what kinds of studies are needed to meet the expectations of stakeholders and end users. This morning at DTx East, a group of panelist discussed the current...
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
There’s no denying that digital therapeutics look and feel different than traditional medications. Instead of popping open a medication bottle, users are logging into an app to access treatment. But the differences don’t stop at the look. While the risk of toxicity is an ever-looming question in the pharma space, the same isn’t true for digital solutions.
Stakeholders at the digital therapeutics...
As more and more partnerships between digital therapeutics and pharma companies begin to emerge, the two industries have started to size each other up. While this may foster an exchange of ideas, there is also the danger of concepts getting lost in translation between the two industries.
Yesterday DTx East in Boston pharma execs talked about the future, realities, and challenges of digital...
